Takeda Pharmaceutical's stock declined 0.64% despite positive Phase 3 trial results for Entyvio (vedolizumab) in pediatric ulcerative colitis patients. The KEPLER trial showed 47.3% of participants achieved clinical remission at week 54, with additional positive secondary endpoints. Technical analysis shows mixed momentum with neutral RSI but bearish MACD signals.

The global blood plasma derivatives market is expected to double from $52.16 billion in 2025 to $104.30 billion by 2033, growing at a 9.08% CAGR. Growth is driven by increasing immune deficiencies, hematological disorders, and neurological conditions, with immunoglobulins representing 41.28% of the market. North America leads with 39.57% market share, while Asia-Pacific is the fastest-growing region at 10.89% CAGR.

The FDA granted Breakthrough Therapy Designation to Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for treating advanced, HPV-unrelated head and neck squamous cell carcinoma in adults. The drug is being evaluated in combination with Merck's Keytruda in an ongoing Phase 3 trial. Additionally, J&J extended its contract with Trellus Health for patient support services through mid-2026.

The global anti-obesity drugs market is estimated at US$22.52 billion in 2026 and is projected to grow at a CAGR of 24.2% to reach US$195.99 billion by 2036, driven by rising obesity rates, improved clinical efficacy of GLP-1 and multi-agonist therapies, and broader recognition of obesity as a chronic disease. However, US trade tariffs are adding cost pressures to pharmaceutical supply chains.

Takeda Pharmaceutical reported Q3 2025 adjusted net profit of 235 billion yen ($1.53B), missing EPS expectations of 55 cents at 47 cents. Sales declined to $7.60B, below consensus of $8.53B, primarily due to generic erosion of Vyvanse for ADHD. Despite the Neuroscience revenue drop of 23.6%, the company raised its 2025 profit guidance citing cost discipline and FX tailwinds. Core operating profit jumped 16.1% to 332.4 billion yen.

COUR Pharma announced publication of research in Science Advances demonstrating how its COUR Nanoparticles (CNPs) induce antigen-specific immune tolerance through the STING/type I interferon pathway. The findings establish a biological foundation for the company's platform and support development across immune-mediated diseases. COUR is currently enrolling patients in Phase 1b/2a studies for type 1 diabetes and myasthenia gravis, with plans to initiate a Phase 2b study in primary biliary cholangitis in 2026.

The U.S. Centers for Medicare & Medicaid Services (CMS) announced the selection of 15 high-cost prescription drugs for the third cycle of the Medicare Drug Price Negotiation Program, marking the first time the initiative includes drugs reimbursed under Medicare Part B. Negotiations will take place in 2026, with prices taking effect January 1, 2028. The second cycle negotiations are estimated to save Medicare $8.5 billion (36% reduction) if prices had been in place in 2024.

The global autologous cell therapy market, valued at $10.12 billion in 2024, is projected to grow to $44.55 billion by 2033 at a CAGR of 17.90%. Growth is driven by rising demand for personalized, patient-derived treatments for chronic diseases including cancer, cardiovascular disorders, and neurodegenerative conditions. North America leads the market with over 44% share, supported by a robust clinical trial ecosystem and regulatory frameworks like the FDA's RMAT designation.

The global amyloidosis therapeutics market is experiencing strong growth, valued at $2.95 billion in 2024 and expected to reach $6.37 billion by 2033 with a 9.20% CAGR. Growth is driven by accelerating ATTR cardiomyopathy diagnosis through imaging technologies, rapid uptake of disease-modifying therapies in North America, and expanded reimbursement in emerging markets like China and Brazil. Five core compounds dominate the market, with chemotherapy remaining the cost-effective backbone for AL amyloidosis treatment.

ResearchAndMarkets.com released a comprehensive clinical trials review for Neurogenic Orthostatic Hypotension (nOH), analyzing global trial landscapes across regions, countries, phases, and sponsor types. The report identifies key trial locations, enrollment trends, and competitive dynamics to support strategic investment decisions in the nOH therapeutics market.

Ascentage Pharma presented its global innovation strategy at the J.P. Morgan Healthcare Conference, highlighting progress with two commercialized hematology products (Olverembatinib and Lisaftoclax) and announcing FDA IND clearance for next-generation BTK degrader APG-3288. The company is advancing multiple Phase III registrational trials and expects significant milestones in 2026 across commercialization, clinical development, and early-stage programs.

The global GPCRs market is projected to grow from USD 3.92 billion in 2024 to USD 6.04 billion by 2032 at a CAGR of 5.59%, driven by rising drug discovery activities, expanding applications in targeted therapeutics, and increasing prevalence of chronic and neurological disorders. The U.S. market is expected to reach USD 1.66 billion by 2032. North America dominates with 37.10% market share, while Asia Pacific shows the fastest growth at 6.12% CAGR. Cell lines and cancer research lead their respective segments.